OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) an Israeli-based developer of CBD-based treatments targeting numerous different medical ailments and disorders reported that it has obtained Institutional Review Board approval to perform safety testing on its patented topical crème compound for the cure of psoriasis and related skin problems. The approval comes after the firm’s February 1, 2017 8K filing reporting an extension to the scope and size of its efficacy trial on the same compound, which commenced in November 2016.
The IRB approved trial covers the cream itself, as a delivery mode, as well as the psoriasis formulation, and is the first to officially make such assertions with the NIH Registry. The trial, which will be done on healthy volunteers at an Israel’s pioneer academic hospitals, is intended to show the safety of the formulation in curing psoriasis on human skin tissue. Managers started soliciting for trial participants as soon as nod was obtained.
Dr. Yehuda Baruch of OWC Pharmaceutical, reported that this nod is an important milestone for company, where their objective is to follow the same rigorous plan common to traditional pharmaceutical advancement to the medical cannabis segment. As posted earlier this year, the report of the efficacy trials was so promising that management determined it was in their interest to extend the scope and size of the trial to assess the biological markers generated to date, among other things.
Dr. Baruch added with each trial they perform, the ability of their formulation to offer relief for psoriasis-linked indications to people suffering from the condition are validated. The trial that was just accepted was intended to assure caregivers and patients that it is safe to utilize outside of lab conditions.
As soon as the company reported the formulation of psoriasis treatment they started getting requests for the product from people suffering from the condition.